Abbott B.V. — China registrations and re-registration filing lines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2026-11-22.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20171057 | Duphalac 乳果糖口服溶液 | 2027-05-22 | 2026-11-22 |
| 国药准字HJ20240082 | Estradiol and Dydrogesterone Tablets 雌二醇地屈孕酮片 | 2029-08-04 | 2029-02-04 |
| 国药准字HJ20150345 | Femoston 雌二醇片/雌二醇地屈孕酮片复合包装 | 2029-10-24 | 2029-04-24 |
| 国药准字HJ20150346 | Femoston 雌二醇片/雌二醇地屈孕酮片复合包装 | 2029-10-24 | 2029-04-24 |
| 国药准字HJ20170221 | Duphaston 地屈孕酮片 | 2031-02-01 | 2030-08-01 |
| 国药准字HJ20160345 | Duspatalin 盐酸美贝维林片 | 2031-03-26 | 2030-09-26 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.